Drug Trial Radar · NCT06361875
A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above
Last checked: Nov 20, 2026Latest source record: Aug 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
908
Actual
Start
Apr 1, 2024
Primary completion
Jun 9, 2025
Study completion Jun 9, 2025
Sponsor
- Lead sponsor
- Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Apr 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study was to evaluate the safety and immunogenicity of a single intramuscular (IM) injection of different formulations of Quadrivalent Influenza Vaccine (QIV) messenger ribonucleic acid (mRNA) (MRT5421, MRT5424, and MRT5429) compared to an active control (QIV- standard dose (SD), QIV- high dose (HD) \[adults ≥ 65 years of age only\], or quadrivalent recombinant influenza vaccine (RIV4)) in adults 18 years of age and older.
Conditions
- Influenza Immunization
- Healthy Volunteers
Interventions
Quadrivalent Influenza mRNA Vaccine MRT5421Biological
Pharmaceutical form:solution in a vial-Route of administration:Intramuscular injection
Quadrivalent Influenza mRNA Vaccine MRT5424Biological
Pharmaceutical form:solution in a vial-Route of administration:Intramuscular injection
Quadrivalent Influenza mRNA Vaccine MRT5429Biological
Pharmaceutical form:solution in a vial-Route of administration:Intramuscular Injection
Quadrivalent Influenza Standard Dose VaccineBiological
Pharmaceutical form: suspension for injection in prefilled syringe -Route of administration:Intramuscular injection
Quadrivalent Influenza High-Dose VaccineBiological
Pharmaceutical form:suspension for injection in pre filled syringe -Route of administration:Intramuscular injection
Quadrivalent Recombinant Influenza VaccineBiological
Pharmaceutical form:suspension for injection in pre filled syringe-Route of administration:Intramuscular injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Immediate Unsolicited Systemic Adverse Events (AEs) After Vaccine AdministrationTime frame: Within 30 minutes after vaccine administration on Day 1
- Number of Participants With Solicited Injection Site Reactions After Vaccine AdministrationTime frame: Within 7 days after vaccine administration on Day 1
- Number of Participants With Solicited Systemic Reactions After Vaccine AdministrationTime frame: Within 7 days after vaccine administration on Day 1
- Number of Participants With Unsolicited Adverse Events After Vaccine AdministrationTime frame: Within 28 days after vaccine administration on Day 1
- Number of Participants With Medically Attended Adverse Events (MAAEs)Time frame: Within 180 days after vaccine administration on Day 1
- Number of Participants With Serious Adverse Events (SAEs) and Adverse Event of Special Interest (AESIs)Time frame: From the vaccine administration (Day 1) until 12 months after vaccine administration, approximately 366 days
- Number of Participants With Abnormal Biological Test ResultsTime frame: Within 8 days after vaccine administration on Day 1
- Geometric Mean of Hemagglutination Inhibition (HAI) Antibody (Ab) Titer at Day 1Time frame: Day 1
- Geometric Mean of Hemagglutination Inhibition Antibody Titer at Day 29Time frame: Day 29
- Percentage of Participants With Detectable Hemagglutination Inhibition Antibody Titer >=1:10 at Day 1Time frame: Day 1
- Percentage of Participants With Detectable Hemagglutination Inhibition Antibody Titer >=1:10 at Day 29Time frame: Day 29
- Geometric Mean Ratio of Hemagglutination Inhibition Antibody Titer at Day 29Time frame: Days 1 and 29
- Percentage of Participants With Seroconversion of Hemagglutination Inhibition Antibody Titer at Day 29Time frame: Day 29
- Percentage of Participants With Hemagglutination Inhibition Antibody Titer >=1:40 at Day 29Time frame: Day 29
- Percentage of Participants With >=2 and >=4 Fold Increase in Hemagglutination Inhibition Antibody Titer at Day 29Time frame: Days 1 and 29
Locations
13 sites in 3 countries. Site status is shown where the registry gives one.
California Research Foundation Site Number : 8400038
San Diego, California
Indago Research and Health Center- Site Number : 8400032
Hialeah, Florida
Cenexel Research Centers of America- Site Number : 8400037
Hollywood, Florida
Brengle Family Medicine Site Number : 8400045
Indianapolis, Indiana
AMR Lexington- Site Number : 8400042
Lexington, Kentucky
Velocity Clinical Research- New Orleans Site Number : 8400053
New Orleans, Louisiana
The Alliance for Multispecialty Research - KCM, LLC- Site Number : 8400034
Kansas City, Missouri
Velocity Clinical Research Norfolk- Site Number : 8400046
Norfolk, Nebraska
AMR Knoxville- Site Number : 8400043
Knoxville, Tennessee
Clinical Trials of Texas, Inc. - PPDS- Site Number : 8400029
San Antonio, Texas
Cenexel JBR- Site Number : 8400051
Salt Lake City, Utah
Investigational Site Number : 3400001
San Pedro Sula, Honduras
Investigational Site Number : 6300002
Barrio Sabana, Puerto Rico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.